Last reviewed · How we verify
NCT06919796
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
Phase 2 trial testing COMIRNATY® in Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers in 40 participants. Not yet recruiting.
1 May 2026
Quick facts
| Lead sponsor | PharmaJet, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 May 2025 |
| Primary completion | 1 May 2026 |
| Estimated completion | 25 November 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- COMIRNATY®
Conditions studied
- Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers — all drugs for Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers →
- SARS CoV-2 — all drugs for SARS CoV-2 →
Sponsor
PharmaJet, Inc. — full company profile →
Who can join
Adults 18 to 50, any sex, with Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers or SARS CoV-2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using needle and syringe
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Emerging polymeric nanocarriers for mRNA and protein therapeutics: design, challenges, and clinical outlook.
Forenzo C, Arnold N, Larsen J. · · 2025 · cited 1× · PMID 40762456 · DOI 10.1080/17435889.2025.2542110 -
Transdermal needle-free drug delivery approaches and activation mechanism.
Sasikala A, Tran DT, Zhang J, Nguyen NT. · · 2026 · PMID 41909222 · DOI 10.1016/j.mtbio.2026.103002
Verify or expand the search:
- PubMed search for NCT06919796
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other PharmaJet, Inc. trials
Trials by the same sponsor.
- NCT06142461 — Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System · Phase 2 · withdrawn
- NCT06002503 — Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06919796 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PharmaJet, Inc.
- Last refreshed: 15 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06919796.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing